Lin Bai

Dr.Bai pursued doctoral studies in Biochemistry and Molecular Biology at Fudan University from September 2018 to June 2024, earning a Ph.D. degree. Since December 2024, she has been serving as a Young Principal Investigator (Young PI) at Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Dr. Bai is currently an independent Young PI. She has long been engaged in proteomics and proteogenomics research, with a primary focus on plasma proteomic biomarker discovery, tumor molecular subtyping and treatment response prediction, systematic identification of DNA modification reader proteins, and mechanisms underlying tumor immune regulation. Her work is dedicated to advancing the translational application of proteomics in precision cancer diagnosis and therapy. In recent years, as first or co-first author, she has published multiple papers in journals including Nature Biomedical Engineering, Advanced Science, Nature Immunology, and Nature Communications. She has established a pan-cancer plasma proteomic profiling strategy, characterized the proteogenomic features of clear cell renal cell carcinoma in response to tyrosine kinase inhibitor (TKI) therapy, systematically charted the landscape of DNA modification readers, and uncovered novel mechanisms such as the regulation of natural killer (NK) cell function through lactylation. These findings demonstrate both mechanistic depth and translational potential.

Selected publications:
1. Bai L*, Lyu J*, Feng J*, Qiao X*, Qu Y*, Yang G*, Zhu Y*, Liao L*, Gao H, Zang A, Xu Z, Ji T, Ran P, Ding W, Zhang H, Zhu L, Wang Y, Wang L, Wang X, Li Y, Li J, Yin X, Zhao G, Liu D, Gao X, Tian S, Tan S, Pu Y, Li L, Song Z, Song J, Guo W, Liao Y#, Ye D#, Yang W#, Jia Y#, Ding C#. Cancer biomarkers discovered using pan-cancer plasma proteomic profiling. Nat Biomed Eng. 2025 Jul 2. doi: 10.1038/s41551-025-01448-y. PMID: 40603747 (co-first author, equal contribution).
2. Bai L, Yang G, Qin Z, Lyu J, Wang Y, Feng J, Liu M, Gong T, Li X, Li Z, Li J, Qin J, Yang W#, Ding C#. Proteome-Wide Profiling of Readers for DNA Modification. Adv Sci (Weinh). 2021 Oct;8(19): e2101426. doi: 10.1002/advs.202101426. Epub 2021 Aug 5. PMID: 34351703; PMCID: PMC8498917 (co-first author, equal contribution).
3. Zhang H*, Bai L*, Wu XQ*, Tian X*, Feng J*, Wu X*, Shi GH*, Pei X*, Lyu J*, Yang G, Liu Y, Xu W, Anwaier A, Zhu Y, Cao DL, Xu F, Wang Y, Gan HL, Sun MH, Zhao JY#, Qu Y#, Ye D#, Ding C#. Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor. Nat Commun. 2023 Jul 17;14(1):4274. doi: 10.1038/s41467-023-39981-6. PMID: 37460463; PMCID: PMC10352361 (co-first author, equal contribution).
4. Lyu J*, Bai L*, Li Y*, Wang X*, Xu Z, Ji T, Yang H, Song Z, Wang Z, Shang Y, Ren L, Li Y, Zang A, Jia Y#, Ding C#. Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy. Nat Commun. 2024 May 8;15(1):3860. doi: 10.1038/s41467-024-47835-y. PMID: 38719824; PMCID: PMC11078984 (co-first author, equal contribution).
5. Jin J*, Yan P*, Wang D*, Bai L*, Liang H, Zhu X, Zhu H, Ding C#, Wei H#, Wang Y#. Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment. Nature Immunology. 2025 Jul;26(7):1099-1112. doi: 10.1038/s41590-025-02178-8. Epub 2025 Jun 10. PMID: 40494934 (co-first author, equal contribution).